Clinical trials: Relapsing Multiple Sclerosis (RMS)
- Condition Relapsing Multiple Sclerosis (RMS)
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Relapsing Multiple Sclerosis
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary…
- Trial name
- GEMINI 1 (NCT04410978)
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 179 sites in United States, Austria and 22 more
- Volunteers
- 974 people
- Sponsor
- Sanofi
Relapsing Multiple Sclerosis
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
This is a study evaluating the effect of fenebrutinib on brain magnetic resonance imaging (MRI) in participants with RMS. The safety and pharmacokinetics of fenebrutinib will also be evaluated.
- Trial name
- FENopta (NCT05119569)
- Testing
- Fenebrutinib
- Where
- 17 sites in United States, Bosnia and Herzegovina and 4 more
- Volunteers
- 109 people
- Sponsor
- Hoffmann-La Roche
Relapsing Multiple Sclerosis (RMS)
Effects of Cladribine Tablets on the PK of Microgynon®
The purpose of this study was to investigate the potential effects of cladribine on the pharmacokinetics (PK) of monophasic oral contraceptive microgynon® by assessment of its constituents, ethinyl estradiol (EE) and…
- Trial name
- NCT03745144
- Testing
- Cladribine, Microgynon®
- Where
- 7 sites in Germany, Poland
- Volunteers
- 28 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.
The Electronic Device - The RebiSmart™ is an electronic injection device that is being studied for the delivery of Merck Serono's Rebif® New Formulation.
- Trial name
- NCT00735007
- Testing
- Rebif® New Formulation (RNF) using RebiSmartTM
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 106 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
- Trial name
- SUNBEAM (NCT02294058)
- Testing
- Ozanimod, Interferon beta-1a
- Where
- 224 sites in United States, Belarus and 23 more
- Volunteers
- 1,346 people
- Sponsor
- Celgene
Relapsing Multiple Sclerosis
Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab
The study provided efficacy, safety, and pharmacokinetics (PK) data for patients with relapsing multiple sclerosis (RMS) in Japan and the other countries
- Trial name
- NCT03249714
- Testing
- Ofatumumab
- Where
- 14 sites in Japan, Russia
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis (RMS)
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV…
- Trial name
- ULTIMATE II (NCT03277248)
- Testing
- Ublituximab, Teriflunomide
- Where
- 13 sites in United States
- Volunteers
- 545 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
This is a randomized, double-blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with RMS…
- Trial name
- MUSETTE (NCT04544436)
- Testing
- Ocrelizumab, Antihistamine, Methylprednisolone
- Where
- 120 sites in United States, Argentina and 19 more
- Volunteers
- 864 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients
The primary purpose of this study is to demonstrate pharmacokinetic bioequivalence of ofatumumab injected by Pre-filled Syringe (PFS) versus Auto-Injector (AI) devices and thereby establish a bridge between the ongoing Phase 3…
- Trial name
- NCT03560739
- Testing
- ofatumumab with PRF, ofatumumab with AI
- Where
- 41 sites in United States, Austria and 7 more
- Volunteers
- 284 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Forms of Multiple Sclerosis
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
The primary objectives of this study are to determine the safety and tolerability of DRF administered for up to 24 weeks in adult East Asian participants with RMS (Part 1) and to determine the safety and tolerability of DRF…
- Trial name
- NCT05083923
- Testing
- Diroximel fumarate
- Where
- 52 sites in China, Japan
- Volunteers
- 136 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing Forms
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and tolerability of ascending intravenous (IV) and subcutaneous (SC) doses of MEDI-551 in adult subjects with relapsing forms of multiple sclerosis (MS).
- Trial name
- NCT01585766
- Testing
- MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, MEDI-551 100 MG-IV
- Where
- 16 sites in United States, Poland and 2 more
- Volunteers
- 56 people
- Sponsor
- MedImmune LLC
Multiple Sclerosis, Relapsing Multiple Sclerosis
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
- Conditions
- Multiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple Sclerosis
- Trial name
- EXCHANGE (NCT03623243)
- Testing
- Siponimod
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic…
- Trial name
- LEMTRADA-ITP (NCT03784898)
- Testing
- Blood draw for future biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis
The Multicenter, Open-label, Single-use Autoinjector Convenience Study
The purpose of this trial is to test the Single-Use Autoinjector for a) ease of use; b) multiple domains related to subject's acceptability and satisfaction, and c) reliability of the correct function for self-injection of Rebif®…
- Trial name
- NCT00958009
- Testing
- Rebidose®
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- EMD Serono
Relapsing Multiple Sclerosis
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod
- Trial name
- FLUENT (NCT03257358)
- Testing
- Fingolimod
- Where
- 66 sites in United States
- Volunteers
- 382 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as assessed by frequent magnetic resonance imaging…
- Trial name
- ATAMS (NCT00642902)
- Testing
- Atacicept
- Where
- 50 sites in United States, Australia and 15 more
- Volunteers
- 255 people
- Sponsor
- EMD Serono
Relapsing-remitting Multiple Sclerosis
Study of Evobrutinib in Participants With RMS
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with Relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT04032171
- Testing
- Evobrutinib, Avonex®
- Where
- 2 sites in United States, Germany
- Volunteers
- 1 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Relapsing Multiple Sclerosis (RMS)
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV…
- Trial name
- ULTIMATE 1 (NCT03277261)
- Testing
- Ublituximab, Teriflunomide
- Where
- 14 sites in United States
- Volunteers
- 549 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis, Relapsing-Remitting
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot…
- Trial name
- NCT04121221
- Testing
- GA Depot
- Where
- 112 sites in United States, Belarus and 8 more
- Volunteers
- 1,016 people
- Sponsor
- Mapi Pharma Ltd.
Relapsing Multiple Sclerosis
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)
Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary…
- Trial name
- GEMINI 2 (NCT04410991)
- Testing
- Tolebrutinib, Teriflunomide HMR1726
- Where
- 186 sites in United States, Argentina and 26 more
- Volunteers
- 899 people
- Sponsor
- Sanofi